Suppr超能文献

印度马哈拉施特拉邦索拉布尔地区HIV-1的亚型多样性及耐药性的出现

Subtype diversity and emergence of drug resistance in HIV-1 in solapur district of Maharashtra, India.

作者信息

Karad Dilip D, Tandon Ravi, Arya Ajay, Sonawane Kailash D, Chavan Anusaya S, Kharat Arun S

机构信息

Department of Microbiology, Shri Shivaji Mahavidyalaya, Barshi, India.

Laboratory of AIDS Research and Immunology, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India.

出版信息

Iran J Microbiol. 2022 Oct;14(5):730-739. doi: 10.18502/ijm.v14i5.10969.

Abstract

BACKGROUND AND OBJECTIVES

Even after four decades, HIV infection remains a global challenge and a leading cause of mortality in adults across the world. Anti-retroviral therapy (ART) that controls HIV viremia, is now available through public health facilities in India but drug resistance, which is likely to develop among these individuals remains poorly studied in India. The objectives of present study are to find out the HIV-1 virus subtypes, drug resistance mutations and HIV-1 drug resistance to NRTI, NNRTI and protease inhibitors in the Solapur district, India.

MATERIALS AND METHODS

In a cross sectional study, forty two ART-experienced HIV-1-infected patients with CD4+ count < 200 cells ml-1 and viral load (VL) > 3, 000 copies ml-1 were recruited. All patients belonged to Maharashtra State of India near Barshi Solapur and had been on ART treatment for over 5 years. EDTA whole blood from HIV-1-infected patients was centrifuged and the viral nucleic acid was purified from the plasma. Viral nucleic acid was amplified by PCR using protease and reverse transcriptase specific primers. The resulting amplicons were sequenced and studied for mutations. The tools from Stanford University website were used for subtyping of HIV-1 and identification of mutations conferring drug resistance.

RESULTS

In present investigation, HIV-1 subtypes were subtype C in 37 (88.09%), subtype CRF01_AE in 2 (4.76%), and subtype A in 3 patients (7.14%). Drug resistance mutations of NRTI, NNRTI and protease were observed in 15 (37.71%) of 42 patients tested. Drug resistance for NRTI was observed in 12 (28.57%) and for NNRTI in 13 (30.95%) patients. No drug resistance was observed for protease inhibitors.

CONCLUSION

Considerable HIV-1 drug resistance exists among patients receiving ART from a rural areas of India, suggesting more studies from rural region are required to prevent development of resistance to ART.

摘要

背景与目的

即便历经四十年,艾滋病毒感染依旧是一项全球性挑战,也是全球成年人死亡的主要原因。如今,印度的公共卫生机构可提供控制艾滋病毒血症的抗逆转录病毒疗法(ART),但这些个体中可能出现的耐药性在印度仍未得到充分研究。本研究的目的是查明印度索拉布尔地区的艾滋病毒-1病毒亚型、耐药性突变以及艾滋病毒-1对核苷类逆转录酶抑制剂(NRTI)、非核苷类逆转录酶抑制剂(NNRTI)和蛋白酶抑制剂的耐药情况。

材料与方法

在一项横断面研究中,招募了42名接受过抗逆转录病毒治疗的艾滋病毒-1感染者,其CD4+细胞计数<200个/毫升,病毒载量(VL)>3000拷贝/毫升。所有患者均来自印度马哈拉施特拉邦靠近巴尔希索拉布尔的地区,且已接受抗逆转录病毒治疗超过5年。将艾滋病毒-1感染者的乙二胺四乙酸(EDTA)全血离心,从血浆中纯化病毒核酸。使用蛋白酶和逆转录酶特异性引物通过聚合酶链反应(PCR)扩增病毒核酸。对所得扩增产物进行测序并研究突变情况。利用斯坦福大学网站的工具对艾滋病毒-1进行亚型分析并鉴定赋予耐药性的突变。

结果

在本研究中,42名接受检测的患者中,37例(88.09%)为艾滋病毒-1 C亚型,2例(4.76%)为CRF01_AE亚型,3例(7.14%)为A亚型。在42例接受检测的患者中,15例(37.71%)观察到NRTI、NNRTI和蛋白酶的耐药性突变。12例(28.57%)患者观察到对NRTI的耐药性,13例(30.95%)患者观察到对NNRTI的耐药性。未观察到对蛋白酶抑制剂的耐药性。

结论

在印度农村地区接受抗逆转录病毒治疗的患者中存在相当程度的艾滋病毒-1耐药性,这表明需要对农村地区开展更多研究以预防对抗逆转录病毒疗法产生耐药性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2c3/9723422/bbfcae10d372/IJM-14-730-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验